Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma

Immunology Letters

Volumn 168, Issue 2, 2015, Pages 260-267

  Flörcken, Anne ^a   Takvorian, Anna ^a   Singh, Anju ^a   Gerhardt, Anne ^a   Ostendorf, Benjamin Nils ^a   Dörken, Bernd ^a   Pezzutto, Antonio ^a   Westermann, Jörg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Flow cytometry; Myeloid derived suppressor cells; Renal cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER PROGNOSIS; CELL ASSAY; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY METASTASIS; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MYELOID DERIVED SUPPRESSOR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; SUPPRESSOR CELL; VERY ELDERLY; BLOOD; BLOOD DONOR; BONE MARROW CELL; FEASIBILITY STUDY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; METASTASIS; MONONUCLEAR CELL; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TIME FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BLOOD DONORS; BLOOD SPECIMEN COLLECTION; CARCINOMA, RENAL CELL; FEASIBILITY STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; KIDNEY NEOPLASMS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYELOID CELLS; NEOPLASM METASTASIS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84949551793     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.10.001     Document Type: Article

References (37)

1. Finke J., Ferrone S., Frey A., Mufson A., Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today 1999, 20(4):158-160.
2. Troy A.J., Summers K.L., Davidson P.J., Atkinson C.H., Hart D.N. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 1998, 4(3):585-593.
3. Uzzo R.G., Rayman P., Kolenko V., Clark P.E., Bloom T., Ward A.M., et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res. 1999, 5(5):1219-1229.
4. Kiertscher S.M., Luo J., Dubinett S.M., Roth M.D. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J. Immunol. 2000, 164(3):1269-1276.
5. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9(3):162-174.
6. Serafini P., De Santo C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 2004, 53(2):64-72.
7. Ochoa A.C., Zea A.H., Hernandez C., Rodriguez P.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 2007, 13(2 Pt. 2):721s-726s.
8. Nagaraj S., Youn J.I., Gabrilovich D.I. Reciprocal relationship between myeloid-derived suppressor cells and T cells. J. Immunol. 2013, 191(1):17-23.
9. Solito S., Marigo I., Pinton L., Damuzzo V., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N. Y. Acad. Sci. 2014, 1319:47-65.
10. Filipazzi P., Huber V., Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 2012, 61(2):255-263.
11. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13(1):23-35.
12. Ko J.S., Zea A.H., Rini B.I., Ireland J.L., Elson P., Cohen P., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009, 15(6):2148-2157.
13. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166(1):678-689.
14. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012, 18(8):1254-1261.
15. Nagaraj S., Gabrilovich D.I. Myeloid-derived suppressor cells in human cancer. Cancer J. 2010, 16(4):348-353.
16. Greten T.F., Manns M.P., Korangy F. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 2011, 11(7):802-807.
17. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009, 69(4):1553-1560.
18. Kotsakis A., Harasymczuk M., Schilling B., Georgoulias V., Argiris A., Whiteside T.L. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J. Immunol. Methods 2012, 381(1-2):14-22.
19. Duffy A., Zhao F., Haile L., Gamrekelashvili J., Fioravanti S., Ma C., et al. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol. Immunother. 2013, 62(2):299-307.
20. Damuzzo V., Pinton L., Desantis G., Solito S., Marigo I., Bronte V., et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B. Clin. Cytom. 2015, 88(March (2)):77-91.
21. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9(1):327-337.
22. Patel P.H., Chaganti R.S., Motzer R.J. Targeted therapy for metastatic renal cell carcinoma. Br. J. Cancer 2006, 94(5):614-619.
23. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356(2):115-124.
24. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24(16):2505-2512.
25. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N. Engl. J. Med. 2007, 356(2):185-187.
26. Ko J.S., Rayman P., Ireland J., Swaidani S., Li G., Bunting K.D., et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010, 70(9):3526-3536.
27. Cao M., Xu Y., Youn J.I., Cabrera R., Zhang X., Gabrilovich D., et al. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab. Invest. 2011, 91(4):598-608.
28. Poschke I., Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin. Immunol. 2012, 144(3):250-268.
29. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58(1):49-59.
30. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002, 20(1):289-296.
31. Mallone R., Mannering S.I., Brooks-Worrell B.M., Durinovic-Bello I., Cilio C.M., Wong F.S., et al. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. Immunol. 2011, 163(1):33-49.
32. Heuvers M.E., Muskens F., Bezemer K., Lambers M., Dingemans A.M., Groen H.J., et al. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patient. Lung Cancer 2013, 81(3):468-474.
33. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005, 65(8):3044-3048.
34. Schmielau J., Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001, 61(12):4756-4760.
35. Kusmartsev S., Eruslanov E., Kubler H., Tseng T., Sakai Y., Su Z., et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 2008, 181(1):346-353.
36. McKenna K.C., Beatty K.M., Vicetti Miguel R., Bilonick R.A. Delayed processing of blood increases the frequency of activated CD11b+ CD15+ granulocytes which inhibit T cell function. J. Immunol. Methods 2009, 341(1-2):68-75.
37. Finke J., Ko J., Rini B., Rayman P., Ireland J., Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 2011, 11(7):856-861.